



Regeneron to Report Fourth Quarter and Full Year 2015 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2016

January 26, 2016

TARRYTOWN, N.Y., Jan. 26, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2015 financial and operating results on Tuesday, February 9, 2016, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information

To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International). A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com. A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.

Regeneron (NASDAQ: [REGN](http://www.regeneron.com)) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:

Investor Relations	Corporate Communications
Manisha Narasimhan, Ph.D.	Hala Mirza
914.847.5126	914.847.3422
manisha.narasimhan@regeneron.com	hala.mirza@regeneron.com

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2015-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-9-2016-300209128.html>

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media